Natco Pharma has reported results for the fourth quarter (Q4FY26) and year ended March 31, 2026.
The company has reported 51.04% drop in its net profit at Rs 209.60 crore for the fourth quarter ended March 31, 2026 as compared to Rs 428.10 crore for the same quarter in the previous year. The total income of the company has decreased by 44.10% at Rs 681.70 crore for Q4FY26 as compared to Rs 1,219.50 crore for the corresponding quarter previous year.
On consolidated basis, the company has reported 34.11% fall in its net profit at Rs 267.90 crore for the fourth quarter ended March 31, 2026 as compared to Rs 406.60 crore for the same quarter in the previous year. The total income of the company decreased by 36.54% at Rs 816.90 crore for Q4FY26 as compared to Rs 1,287.30 crore for the corresponding quarter previous year.
For the year ended March 31, 2026, the company has reported 30.74% fall in its net profit at Rs 1,281.50 crore as compared to Rs 1,850.40 crore for the previous year. The total income of the company has decreased by 12.23% at Rs 3,875.70 crore for year under review as compared to Rs 4,415.80 crore for year ended March 31, 2025.
For the year ended March 31, 2026, on the consolidated basis, the company has reported 24.76% fall in its net profit at Rs 1,418.50 crore as compared to Rs 1,885.40 crore for the previous year. The total income of the company decreased by 8.53% at Rs 4,375.90 crore for year under review as compared to Rs 4,784.00 crore for year ended March 31, 2025.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1779.35 |
| Dr. Reddys Lab | 1267.05 |
| Cipla | 1397.75 |
| Zydus Lifesciences | 1085.45 |
| Lupin | 2248.70 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: